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OBJECTIVES: To assess the relative cost-effectiveness of
olanzapine compared to risperidone in the treatment of
acute episodes and long-term maintenance of schizo-
phrenia in Italy. METHODS: A decision analysis ap-
proach (based on semi-markov modelling techniques) was
used to consider the costs and health outcomes of initi-
ating treatment on patients with an acute episode of schiz-
ophrenia and a history of relapsing with no prior atypical
antipsychotic treatment. The model allowed two alterna-
tive atypical antipsychotics to be used before considering
patients as being treatment resistant. Clinical response
rates were based on changes in BPRS/PANSS scores
(40% improvement) taken from randomised clinical
trials. Relapse rates for the ﬁrst year of treatment were
based on literature estimates. Resource use data covering
periods in acute episode, stable maintenance and acute
relapse health states were based on a combination of pub-
lished data and clinical opinion. The model was used to
compare the costs and health outcomes of olanzapine
versus risperidone as 1st line treatment choices over a 3-
year period. RESULTS: The base case analysis showed
that 1st line use of olanzapine resulted in a reduction of
relapses over the 3-year period (37 versus 38 per 100
patients treated). The olanzapine 1st line strategy was
associated with an overall cost saving over risperidone of
around €50,822 per 100 patients treated (approximately
a 2% cost reduction) despite the increased drug costs
(€6.64 versus €4.19 per day). CONCLUSIONS: With 
the context of the Italian health care services the use of
olanzapine as a 1st line atypical antipsychotic appears to
provide cost-effective health outcomes advantages over
risperidone.
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OBJECTIVES: Clozapine is a drug of choice for treating
neuroleptic resistant schizophrenia, but it has serious side
effects. Risperidone has shown efﬁcacy in managing 
neuroleptic-resistant schizophrenia, without agranulocy-
tosis. To our knowledge, economic evaluations of both
drugs in this patient population have not been performed.
The objective of this study was to estimate a difference in
hospitalization costs for schizophrenic patients on cloza-
pine vs. risperidone over one-year period. METHODS:
Estimates of length of stay (LOS) reduction in patients
receiving the clozapine or risperidone were obtained from
the medical literature by searching MEDLINE and
HEALTHSTAR. Two articles examining LOS reduction
for patients receiving risperidone and clozapine were
identiﬁed, and yearly reduction in LOS was examined. To
estimate a reduction in hospitalization costs, average
daily hospitalization charges from the Healthcare Cost
and Utilization Project database were obtained for 
the diagnosis of schizophrenia (deﬁned as ICD9-
codes 295.40–295.45, 295.80–295.82, 295.85, 295.90–
295.92, and 295.95). Hospital charges were converted to
costs by using a cost-to-charge ratio. All costs were
expressed in 2000 US dollars. RESULTS: After starting
risperidone, 35 patients had a decrease in LOS by 51 days
per year. After starting clozapine, 172 patients had a 132-
day decrease in LOS per year, with a difference of 81 
hospitalization days, favoring clozapine. The resulting
difference in hospitalization costs between patients on
clozapine and risperidone patients was estimated as
$1,052 per inpatient day. Estimated beneﬁts of reducing
hospitalization costs for clozapine patients as compared
to risperidone were $85,212 per patient per year. CON-
CLUSIONS: Clozapine seems to result in reduction in
LOS, potentially leading to lower costs of treating schiz-
ophrenic patients, as compared to risperidone. More
studies are necessary to quantify economic impact of
clozapine in this patient population.
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OBJECTIVE: To estimate the costs and effects of 
long-acting risperidone (the ﬁrst long-acting injectable
atypical) as ﬁrst-line treatment for non-compliant schizo-
phrenic patients, versus a conventional depot and con-
tinuing short-acting oral atypical formulations over a ﬁve
year period in the Netherlands. METHODS: A discrete
event model was developed comparing three scenarios. In
scenario 1, patients start with haloperidol depot, after
which they may be treated with olanzapine and clozap-
ine. Scenario 2 is similar to 1 except that patients start
with long-acting risperidone. In scenario 3, patients start
(or continue) with olanzapine, after which they may sub-
sequently be treated with risperidone (oral) and clozap-
ine. The model takes account of patient characteristics
